Vanda Pharmaceuticals, Inc. (VNDA) Posts Q2 Loss of 28c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $4.57 +0.88%
EPS Growth %: -78.9%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
HOVR, VFS, PGR, More
EPS Growth %: -78.9%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q2 EPS of ($0.28), $0.01 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $8.38 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Aritzia (ATZ:CN) (ATZAF) PT Raised to Cdn$228 at UBS on Strong Growth
- Alibaba ADR climbs on analyst upgrades, AI momentum
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
